AIMT News and Press, Aimmune Therapeutics Inc. From 05/16/19

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 20...

- Company Enters into Commercial Supply Agreement for AR101 - Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that...

CymaBay Therapeutics ( CBAY ) : The company announced first quarter financial results, with management highlighting the fact that enrollment was completed one quarter ahead of schedule in the phase 2b study of seladelpar in NASH patients (52-week, dose-ranging trial). Topline data for chang...

Aimmune Therapeutics, Inc. (AIMT) Q1 2019 Earnings Conference Call May 08, 2019 4:30 PM ET Company Participants Eric Bjerkholt - Chief Financial Officer Jayson Dallas - President & Chief Executive Officer Dan Adelman - Chief Medical Officer Andrew Oxtoby - Chief Commercial ...

Aimmune Therapeutics (NASDAQ: AIMT ): Q1 GAAP EPS of -$0.87 beats by $0.10. More news on: Aimmune Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Potential FDA approval of AR101 for peanut allergy expected by late January 2020; Company on target to be launch-ready in Q4 2019 Submission of marketing application for AR101 in Europe on track for mid-2019, following positive topline results of ARTEMIS European Phase 3 trial ...

AAOI , AIMT , AKCA , ALB , ANGI , APLE , ARNA , ASRT , AXGN , BIO , BREW , CCMP , CECO , CNDT , COLL , CPA , CTL , CVNA , CW , CWH , CXW , DAR , DHT , DIS , DRH , DVAX , ECPG , EGAN , ELF , ENV , ET , ETSY , EVRG , EZPW , FLNT , FNV , FOSL , FOXA , FTK...

Aimmune Therapeutics (NASDAQ: AIMT ) is scheduled to announce Q1 earnings results on Tuesday, May 7th, after market close. More news on: Aimmune Therapeutics, Inc., Earnings news and commentary, , Healthcare stocks news, Read more ...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday, May 8, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 20...

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...